MYD88 and diffuse large B-cell lymphoma: However, the frequency of MYD88 variants in our cohort of primary OA-DLBCL-NOS does not match that of LBCL of immune-privileged sites (60–78%) [24,25,26,27], or extranodal LBCLs with high non-GCB frequencies, including primary breast DLBCL-NOS (39–56%) [28,29], primary cutaneous DLBCL, leg type (75–79%) [30,31], intravascular LBCL (44–57%) [32,33,34], or primary sinonasal DLBCL-NOS (approx. 50%) [35].